MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,253.00
+15.00 (1.21%)
Feb 21, 2025, 9:00 AM KST
-25.86%
Market Cap 47.28B
Revenue (ttm) 17.08B
Net Income (ttm) 6.67B
Shares Out 37.73M
EPS (ttm) 194.56
PE Ratio 7.09
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,518
Average Volume 136,761
Open 1,205.00
Previous Close 1,238.00
Day's Range 1,205.00 - 1,253.00
52-Week Range 999.00 - 4,500.00
Beta 0.67
RSI 57.92
Earnings Date Mar 21, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 51
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.